Abcalis — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Abcalis is a private, pre-revenue biotech platform company leveraging Nobel Prize-winning phage display technology to produce animal-free, recombinant antibodies. Its core business model combines custom antibody services and product licensing, targeting the diagnostics and life science research markets with a focus on reproducibility, specificity, and sustainability. The company has gained recognition through awards and participates in research consortia, positioning itself as an ethical and technologically advanced alternative to traditional antibody production methods.

Antibodies

Technology Platform

Phage display technology for animal-free, recombinant antibody generation, including naïve library generation, selection, affinity maturation, and custom format conversion (Fc-engineering, species choice, tag fusion).

Opportunities

The growing pressure for reproducibility in science and diagnostics, coupled with increasing regulatory scrutiny and a global shift toward reducing animal use in research, creates a significant market opportunity for defined, recombinant antibodies.

The ability to offer unlimited reproducibility and supply security is a key value proposition for diagnostic manufacturers.

Risk Factors

The company faces intense competition from large, established reagent suppliers and must overcome customer inertia and cost-sensitivity associated with switching from traditional antibodies.

Its success is also dependent on continued external funding until it achieves sustainable revenue from licenses and services.

Competitive Landscape

Abcalis competes in the recombinant antibody space against larger reagent companies (e.g., Absolute Antibody, Bio-Rad) and therapeutic discovery platforms that also offer services. Its differentiation lies in its focused 'animal-free' ethical branding, end-to-end custom service for diagnostics, and its proprietary Multiclonals™ product concept.

More companies in Biologics / Biosimilars →More companies in Germany →